All In Biotech

Drug Trial Radar · NCT02177773

GA-68 DOTA-TOC of Somatostatin Positive Malignancies

Evaluation of Gallium-68 DOTA-TOC Imaging of Somatostatin Receptor Positive Malignancies

Last checked: Nov 20, 2026Latest source record: Nov 12, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

300

Actual

Start

Jun 23, 2014

Primary completion

Aug 7, 2017

Study completion Aug 7, 2017

Sponsor

Lead sponsor
University of California, San FranciscoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Peterson Family Foundation
First posted
Jun 30, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I/II trial studies how well gallium Ga 68-DOTA-TOC positron emission tomography (PET)/computed tomography (CT) or PET/magnetic resonance imaging (MRI) works in imaging patients with somatostatin receptor positive tumors. Gallium Ga 68-DOTA-TOC binds to somatostatin receptor positive tumors and can be seen using a PET scan. A PET scan uses a special camera to detect energy given off from gallium Ga 68-DOTA-TOC, to make detailed pictures of areas where material accumulates in the body. Diagnostic procedures, such as gallium Ga 68-DOTA-TOC PET/CT or PET/MRI, may help find and diagnose somatostatin receptor positive tumors and help plan the best treatment.

Conditions

  • Neuroendocrine Tumor
  • Paraganglioma
  • Carcinoid Tumors
  • Neuroblastoma

Interventions

  • Computed Tomography (CT)Procedure

    Undergo Gallium Ga 68-DOTA-TOC PET/CT

  • Gallium Ga 68-EdotreotideDrug

    Given Intravenously (IV) before imaging

  • Magnetic Resonance Imaging (MRI)Procedure

    Undergo gallium Ga 68-DOTA-TOC PET/MRI

  • Positron Emission Tomography (PET)Procedure

    Undergo gallium Ga 68-DOTA-TOC PET in combination with CT or MRI

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Lesions as Determined by Gallium Ga 68-DOTA-TOC Positron Emission Tomography (PET) ImagingTime frame: 1 day
  2. Standardized Uptake Value Maximum (SUVmax)Time frame: 1 day
  3. Inter-reader VariabilityTime frame: 1 day

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of California, San Francisco

    San Francisco, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.